

TID 2016

Pre-Meeting of
TTS 2016 Congress

10th International Transplant Infectious Disease Conference

Hong Kong • August 18, 2016 • www.tts.org/tid



TTS-TID WEBINAR MARCH 31, 2016 RECORDING IS POSTED



ZIKA VIRUS

Speaker: Clarisse Machado

Moderator: Michele I. Morris



[CLICK HERE TO VIEW \(YOU MUST BE LOGGED INTO THE WEBSITE\)](#)

ZIKA VIRUS INFECTION: INFORMATION FOR THE TRANSPLANT PROFESSIONAL

Clarisse M. Machado, M.D.
Head of the Virology Laboratory, Institute of Tropical Medicine
University of São Paulo, Brazil
President-Elect of the TID section.

Zika virus (ZIKV) is a RNA virus of the Flaviviridae family, genus Flavivirus, which includes other well-known arboviruses such as West Nile virus (WNV), dengue virus (DENV) and yellow fever virus (YFV), the latter two also transmitted by Aedes mosquitoes.

More than half of the world's human population lives in areas infested with Aedes; consequently, large urban epidemics of Zika, dengue, chikungunya, and even yellow fever have been expected for decades.

Although ZIKV was isolated from a rhesus monkey in the Zika forest of Uganda in 1947, the virus was largely ignored until 2007 when it caused an epidemic on the island of Yap in Micronesia and Gabon^[1] followed by an outbreak in French Polynesia during 2013^[2]. Deleterious consequences of these epidemics were not noticed in those countries, possibly due to the low population density. However, in early 2015, when ZIKV epidemics hit the northeast region of Brazil, a populous country infested by both Aedes aegypti and A. albopictus, the epidemic showed its true colors. The apparently mild acute infection was associated with serious consequences, such as the increase in the number of cases of Guillain-Barre (already seen after the French Polynesia epidemic) and microcephaly, in ZIKV epidemic regions.

Although not yet proven, a causal relationship between Zika infection during pregnancy and microcephaly is strongly suggested^[3]. Meanwhile, reports of sexual and blood transmitted ZIKV infections have increased the controversy associated with the epidemic^{[4],[5]}.


So far, no cases of Zika virus have been reported in transplant recipients. Transmission by solid organ or marrow transplantation is theoretically possible since the virus can be transmitted through blood transfusion. It is not known if the disease is more or less severe in the immunocompromised patient. Therefore, it is important for the transplant community to be aware of the risk of ZIKV infections.

Infection with ZIKV is asymptomatic in most people. In symptomatic patients, fever, rash, conjunctivitis, or joint pain are the most common symptoms. Myalgia, asthenia and headache can also occur. The incubation period varies from a few days to a week, and symptoms typically resolve within a week. Severe disease and/or death appear to be very rare in the immunocompetent population. There is currently no vaccine and no treatment for Zika infection. Management of immunosuppressive drugs may be helpful to avoid severe symptoms and lymphopenia. However, the level of evidence for this recommendation is low.

Clinical presentation may help in the differential diagnosis in case of co-circulation of DENV and Chikungunya (CHKV). The main signs and symptoms observed in infections caused by ZIKV, DENV and CHKV are shown in the table below.

SIGNS AND SYMPTOMS	DENGUE	CHIKUNGUNYA	ZIKA
Fever	++++	++++	+
Rash (maculopapular)	++	++	++++
Conjunctivitis	+	+	++++
Myalgia/arthritis	+++	+++++	++
Edema	Absent	++++	+++
Retro-orbital pain	+++++	++	+
Lymphadenopathy	+	++	+
Bleeding	++	Absent	Absent
Hepatomegaly	++	+++	Absent
Lymphopenia/ thrombocytopenia	+++	+++	Absent

Preventive policies are focused on vector control and infection avoidance. Community-based programs are important to keep the environment free of potential breeding sources.



Transplant recipients should receive information about the modes of Zika transmission and Aedes mosquito habits in order to avoid exposure, and they should comply with the protective measures. Additionally, they have to be aware of the main clinical signs and potential complications, and seek medical care in case of symptoms.

Based on current available information, the following recommendations should be shared with transplant patients:

Evaluation of epidemiological risk Investigation of the epidemiological risk is mandatory and should focus especially upon travel to epidemic regions. Up until February 3rd 2016, 35 cases of travel-associated ZIKV diseases had been reported in the US^[6].

Graft-transmission Be aware that ZIKV infection results in an asymptomatic viremia in most people, consequently, donors travelling from epidemic regions might be infected. It is not known which organs might become infected with ZIKV or how long the infectious virus might be present in those organs.

In case of living donors with history of Zika infection, donation should be deferred whenever possible. For blood donation, the minimal deferral time recommended by the FDA is 28 days after returning from ZIKV regions.

Serological tests for Zika virus are not yet available, nor have they been validated for routine donor screening. The risk of donor-derived infection should be balanced with the benefits of transplantation on an individual basis.

At this moment, donor screening by PCR is not recommended in SOT, but should be considered in allogeneic HSCT in epidemic regions.

Diagnosis of ZIKV infection For symptomatic patients, diagnosis entails real time PCR in blood or urine samples within the first 7 days or up to 14 days, respectively. Serology is not yet available.

To avoid unnecessary testing, a case definition approach to ZIKV investigation should be applied. For example, rash and/or fever, along with one of the following symptoms: headache, myalgia, arthralgia and conjunctivitis should prompt diagnostic investigation of suspected cases.

Health services should provide rapid and sensitive diagnosis, and include DENV and CHKV tests in regions with co-circulation of the three viruses.

Mosquito habits The Aedes is a domestic mosquito, living in or around homes or other places frequented by people such as schools or churches. It generally bites at dawn and dusk. However, even in the hottest daytime hours, it can attack in the shade, inside or outside the home.

The mosquitoes breed in calm, clear water. In favorable environmental conditions, development into an adult mosquito takes around 10 days after emergence from the egg. Therefore, the elimination of standing water should be performed at least once a week to interrupt the mosquito life cycle.

References

- [1]. Grard G, Caron M, Mombo IM, Nkoghe D, Mboui Ondo S, Jiolle D, et al. Zika Virus in Gabon (Central Africa) - 2007: A New Threat from *Aedes albopictus*? *PLoS Negl Trop Dis*. 2014;8(2)
- [2]. Ioos S, Mallet HP, Leparac Goffart I, Gauthier V, Cardoso T, Herida M. Current Zika virus epidemiology and recent epidemics. *Med Mal Infect*. Elsevier Masson SAS; 2014;44(7):302-7.
- [3]. Schuler-Faccini L, Ribeiro EM, Feitosa IML, Horovitz DDG, Cavalcanti DP, Pessoa A, et al. Possible Association Between Zika Virus Infection and Microcephaly — Brazil, 2015. *MMWR Morb Mortal Wkly Rep*. 2016;65(3):59-62.
- [4]. Musso D, Roche C, Robin E, Nhan T, Teissier A, Cao-Lormeau VM. Potential sexual transmission of zika virus. *Emerg Infect Dis*. 2015;21(2):359-61.
- [5]. Reuters. Zika Spread Through Blood Transfusion in Brazil [Internet]. 2016. Available from: <http://time.com/4208187/brazil-zika-blood-transfusion>
- [6]. Centers for Disease Control and Prevention (CDC). Zika virus [Internet]. 2016. Available from: <http://www.cdc.gov/zika/index.html>

HISTORY & MISSION

9TH CONFERENCE RECORDINGS

8TH CONFERENCE RECORDINGS

7TH CONFERENCE RECORDINGS

6TH CONFERENCE RECORDINGS

5TH CONFERENCE RECORDINGS

4TH CONFERENCE RECORDINGS

ONLINE ACCESS TO TID JOURNAL

PAY YOUR DUES

TID CHAT SIGNUP

Login to your member account to subscribe to our listserv.

Subscribing not allowed for unregistered users. Please login first.



